Genmab — Juli 2016
-
-
Vi slutter højt.
-
Enorm volumen sådan en sommerdag...
-
- Luk i HOD.
- Luk i HOD.
-
Det plejer det at blive efter HOD.
-
Lidt om Myeloma i US: http://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq#section/all
-
-
Commenting on the breakthrough status, Craig L. Tendler, MD, vice president, Late-Stage Development and Global Medical Affairs for Oncology, Hematology, and Supportive Care at Janssen, said, “This is an important recognition of the transformative potential of daratumumab and its possible benefit as a backbone therapy in combination with 2 of the most widely used regimens for multiple myeloma.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind